Sorrento Therapeutics to Present at the Biotech Showcase 2014 and the 7th Annual OneMed Forum SF2014 in San Francisco
SAN DIEGO, Jan. 10, 2014 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento; www.sorrentotherapeutics.com) announced today that Dr. Henry Ji, President and Chief Executive Officer of Sorrento, will present a corporate overview at the following events next week in San Francisco:
Event: Biotech Showcase 2014 When: Monday, January 13, 2014 at 3:00 PM PT Parc 55 Wyndham San Francisco Union Square Hotel; 3rd Floor Track D Where: (Powell)
A live webcast of the presentation can be accessed through the investor relations section of the Company’s website at www.sorrentotherapeutics.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days.
Event: 7th Annual OneMed Forum SF2014 When: Tuesday, January 14, 2014 at 2:50 PM PT Where: The Westin San Francisco Market Street
In addition, Richard Vincent, EVP and Chief Financial Officer, will participate in a round table discussion on optimizing financial performance of small cap biotech companies:
Event: Life Science Leader Executive Networking Series Round Table Discussion: Optimizing Small Biotech Market Caps When: Tuesday, January 14, 2014 at 7:30 AM -9:00 AM PT Where: Sir Francis Drake Hotel in San Francisco; Starlight Room (21st Floor)
About Sorrento Therapeutics, Inc.
Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento’s most advanced asset is Cynviloq(TM), the next-generation paclitaxel, which will commence its registrational trial and be developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing resiniferatoxin (RTX), a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the National Institutes of Health to treat terminal cancer patients suffering from intractable pain. The company has made significant advances in developing human monoclonal antibodies, complemented by a comprehensive and fully integrated antibody drug conjugate (ADC) platform that includes proprietary conjugation chemistries, linkers, and toxic payloads. Sorrento’s strategy is to enable a multi-pronged approach to combating cancer with small molecules, therapeutic antibodies, and ADCs.
This press release contains forward-looking statements under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the potential for products to be successfully developed using the abbreviated 505(b)(2) regulatory pathway or the monoclonal antibodies and ADC technologies; the synergies and prospects for a combined enterprise going forward, including the retention of key personnel; and the clinical development and commercial potential of conjugated antibodies that may be developed based on the acquired technologies; the potential for claims from third parties regarding the use of the antibody-drug conjugates and related technology that may be developed from the merger; the costs and expenses associated with the merger and additional clinical development programs from successful product development efforts; and other matters that are described in Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2012, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.
SOURCE Sorrento Therapeutics, Inc.